Treatment of hypertension in various racial subgroups Donald G. Vidt Clinical Trials Report Pages: 312 - 313
Antihypertensive drugs and incidence of type 2 diabetes: Evidence and implications for clinical practice Samuel AsfahaRaj Padwal OriginalPaper Pages: 314 - 322
Management of hypertension in overweight and obese patients: A practical guide for clinicians Francesco DentaliArya M. SharmaJames D. Douketis OriginalPaper Pages: 330 - 336
HMG-CoA reductase inhibitors and the kidney Vito M. CampeseBassel HadayaJosephine Chiu OriginalPaper Pages: 337 - 342
The role of aldosterone antagonists in the management of resistant hypertension Mari K. NishizakaDavid A. Calhoun OriginalPaper Pages: 343 - 347
Hypertension in pregnancy Maryann MugoGurushankar GovindarajanSamy I. McFarlane OriginalPaper Pages: 348 - 354
Should the target for blood pressure control specify both a systolic and a diastolic component? Christopher J. HebertGanesh ShidhamLee A. Hebert OriginalPaper Pages: 360 - 362
The African American Study of Kidney Disease: Do these results indicate that 140/90 mm Hg is good enough? Mahboob RahmanAshraf El-MeanawyJoseph Romanello OriginalPaper Pages: 363 - 366
Antihypertensive, antiproteinuric therapy and myocardial infarction and stroke prevention Kenneth L. ChoiWilliam J. Elliott OriginalPaper Pages: 367 - 373
Proteinuria reduction: Mandatory consideration or option when selecting an antihypertensive agent? Robert D. Toto OriginalPaper Pages: 374 - 378
Microalbuminuria and C-reactive protein: Similar messengers of cardiovascular risk? Stephan J. L. BakkerRon T. GansevoortDick de Zeeuw OriginalPaper Pages: 379 - 384
Does dietary salt increase the risk for progression of kidney disease? Shiraz I. MishraCharlotte Jones-BurtonMatthew R. Weir OriginalPaper Pages: 385 - 391